Published in Oncogene on June 03, 1999
Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet (2010) 4.26
Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev (2003) 2.38
DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol (2009) 2.35
Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol Cell Biol (2004) 2.23
Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nat Struct Mol Biol (2009) 2.08
Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol (2001) 1.99
Natural and pharmacological regulation of telomerase. Nucleic Acids Res (2002) 1.92
Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc Natl Acad Sci U S A (2002) 1.75
Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer. J Biol Chem (2012) 1.47
Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol Cell Biol (2005) 1.44
Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol (2004) 1.26
HPV-16 E7 reveals a link between DNA replication stress, fanconi anemia D2 protein, and alternative lengthening of telomere-associated promyelocytic leukemia bodies. Cancer Res (2008) 1.07
Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres. PLoS One (2012) 1.04
A mutation in the STN1 gene triggers an alternative lengthening of telomere-like runaway recombinational telomere elongation and rapid deletion in yeast. Mol Cell Biol (2005) 1.03
Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX. Nat Commun (2015) 1.03
Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells. J Cell Biol (2012) 1.02
PML body meets telomere: the beginning of an ALTernate ending? Nucleus (2012) 0.94
ATRX represses alternative lengthening of telomeres. Oncotarget (2015) 0.88
Telomerase activity in pleural malignant mesotheliomas. Lung Cancer (2011) 0.86
Human telomerase reverse transcriptase (hTERT) promotes gastric cancer invasion through cooperating with c-Myc to upregulate heparanase expression. Oncotarget (2016) 0.84
ALTernative Telomere Maintenance and Cancer. Trends Cancer (2015) 0.82
Telomere maintenance mechanisms in cancer: clinical implications. Curr Pharm Des (2014) 0.82
Molecular and cellular evidence for the alternative lengthening of telomeres (ALT) mechanism in chicken. Cytogenet Genome Res (2011) 0.80
Tiptoeing to chromosome tips: facts, promises and perils of today's human telomere biology. Philos Trans R Soc Lond B Biol Sci (2002) 0.77
In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF (V600E) mutation. Virchows Arch (2016) 0.76
The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype. Genes (Basel) (2016) 0.75
Stable expression of promyelocytic leukaemia (PML) protein in telomerase positive MCF7 cells results in alternative lengthening of telomeres phenotype. Genome Integr (2012) 0.75
Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX. Sci Rep (2016) 0.75
Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med (1997) 6.55
Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science (1991) 6.15
Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J (1995) 6.03
Telomere maintenance by recombination in human cells. Nat Genet (2000) 5.14
Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res (1999) 4.24
Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet (1997) 3.56
The APC gene product in normal and tumor cells. Proc Natl Acad Sci U S A (1993) 3.25
Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet (2003) 2.26
Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol (2001) 1.99
The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit. Hum Mol Genet (1997) 1.97
Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res (1991) 1.88
Telomere dynamics and telomerase activity in in vitro immortalised human cells. Eur J Cancer (1997) 1.87
Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol (1995) 1.85
Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic antitumor agents. J Med Chem (1998) 1.71
Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res (2000) 1.70
Human bronchial epithelial cells with integrated SV40 virus T antigen genes retain the ability to undergo squamous differentiation. Differentiation (1988) 1.64
The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia (2001) 1.60
SV40-induced immortalization of human cells. Crit Rev Oncog (1994) 1.51
Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol (1989) 1.51
Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol (1983) 1.49
Antitumor agents. Part 204: synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg Med Chem Lett (2001) 1.48
Telomere length dynamics in telomerase-positive immortal human cell populations. Exp Cell Res (1998) 1.47
Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res (1998) 1.45
Telomere maintenance mechanisms and cellular immortalization. Curr Opin Genet Dev (1999) 1.43
Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem (1998) 1.43
Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene (2007) 1.42
Strontium phosphate transfection of human cells in primary culture: stable expression of the simian virus 40 large-T-antigen gene in primary human bronchial epithelial cells. Mol Cell Biol (1987) 1.39
Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Res (1985) 1.37
Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep (1982) 1.37
Mammalian stanniocalcins and cancer. Endocr Relat Cancer (2003) 1.35
Methylation of the human telomerase gene CpG island. Cancer Res (2000) 1.31
Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res (1987) 1.30
A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol (1995) 1.30
Characteristics of tumor cell bioactivity in oncogenic osteomalacia. Mol Cell Endocrinol (1996) 1.25
Alternative lengthening of telomeres in human cells. Radiat Res (2001) 1.22
Immortalized cells with no detectable telomerase activity. A review. Biochemistry (Mosc) (1997) 1.11
Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. Biochem J (2000) 1.10
Correction of the copper transport defect of Menkes patient fibroblasts by expression of the Menkes and Wilson ATPases. J Biol Chem (1998) 1.10
Assignment of SV40-immortalized cells to more than one complementation group for immortalization. Exp Cell Res (1993) 1.10
p16(INK4a) and the control of cellular proliferative life span. Carcinogenesis (1999) 1.08
Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein. Oncogene (1998) 1.03
Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro. Cancer Res (1983) 1.02
Germ-line splicing mutation of the p53 gene in a cancer-prone family. Cell Growth Differ (1992) 1.01
A highly expressed 81 kDa protein in immortalized mouse fibroblast: its proliferative function and identity with ezrin. Oncogene (1996) 1.00
Identification of a second stanniocalcin cDNA in mouse and human: stanniocalcin 2. Mol Cell Endocrinol (1998) 0.98
Neoplastic transformation of a human bronchial epithelial cell line by a recombinant retrovirus encoding viral Harvey ras. Mol Carcinog (1988) 0.97
Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. Eur J Cancer Clin Oncol (1983) 0.97
Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen. Cancer Res (1984) 0.96
Association of extended in vitro proliferative potential with loss of p16INK4 expression. Oncogene (1996) 0.95
In vitro transformation of Li-Fraumeni syndrome fibroblasts by SV40 large T antigen mutants. Oncogene (1994) 0.95
Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress. Oncogene (2009) 0.95
An N-terminal region of mot-2 binds to p53 in vitro. Neoplasia (2001) 0.95
Finite life span of hybrids formed by fusion of different simian virus 40-immortalized human cell lines. J Virol (1992) 0.94
HPV-16 E6 and E7 genes, like SV40 early region genes, are insufficient for immortalization of human mesothelial and bronchial epithelial cells. Exp Cell Res (1994) 0.94
Correlation between complementation group for immortality and the cellular distribution of mortalin. Exp Cell Res (1995) 0.93
Telomerase recruitment to telomeres. Cytogenet Genome Res (2009) 0.92
Pex19p dampens the p19ARF-p53-p21WAF1 tumor suppressor pathway. J Biol Chem (2001) 0.90
Involvement of RB-1, p53, p16INK4 and telomerase in immortalisation of human cells. Oncogene (1995) 0.90
Effects of simian virus 40 T-antigens on normal human mammary epithelial cells reveal evidence for spontaneous alterations in addition to loss of p16(INK4a) expression. Exp Cell Res (2001) 0.90
Transformation of human neonatal prostate epithelial cells by strontium phosphate transfection with a plasmid containing SV40 early region genes. Cancer Res (1989) 0.89
Similar simian virus 40-induced immortalization frequency of fibroblasts and epithelial cells from human large airways. Cell Mol Biol Res (1993) 0.88
Normal telomere maintenance in immortal ataxia telangiectasia cell lines. Mutat Res (1997) 0.87
Identification of a 55-kDa ezrin-related protein that induces cytoskeletal changes and localizes to the nucleolus. Exp Cell Res (1999) 0.86
Downregulation of metallothionein-IIA expression occurs at immortalization. Oncogene (1999) 0.86
Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents. J Med Chem (2001) 0.86
Molecular cloning and characterization of mouse stanniocalcin cDNA. Mol Cell Endocrinol (1996) 0.86
The distribution of stanniocalcin 1 protein in fetal mouse tissues suggests a role in bone and muscle development. J Endocrinol (2000) 0.85
Invasive and metastatic potential of a v-Ha-ras-transformed human bronchial epithelial cell line. J Natl Cancer Inst (1989) 0.85
Inhibition of SV40 large T antigen induced apoptosis by small T antigen. Oncogene (1999) 0.85
Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. Eur J Cancer Clin Oncol (1984) 0.85
Control of growth and squamous differentiation in normal human bronchial epithelial cells by chemical and biological modifiers and transferred genes. Environ Health Perspect (1989) 0.84
Human mesothelioma cells and asbestos-exposed mesothelial cells are selectively resistant to amosite toxicity: a possible mechanism for tumor promotion by asbestos. Carcinogenesis (1992) 0.84
Structurally and functionally distinct mouse hsp70 family members Mot-1 and Mot-2 proteins are encoded by two alleles. DNA Res (2000) 0.83
Constructing immortalized human cell lines. Curr Opin Biotechnol (1999) 0.81
Cloning and characterization of a novel gene, striamin, that interacts with the tumor suppressor protein p53. J Biol Chem (1999) 0.80
Stanniocalcin 1 is important for poststroke functionality, but dispensable for ischemic tolerance. Neuroscience (2012) 0.80
Cell cycle effects of iron depletion on T-47D human breast cancer cells. Exp Cell Res (1985) 0.79
Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase. Oncogene (2009) 0.79
Genetic changes associated with immortalization. A review. Biochemistry (Mosc) (1997) 0.79
Transcriptional inactivation of p53 by deletions and single amino acid changes in mouse mot-1 protein. Biochem Biophys Res Commun (2000) 0.79
Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Exp Cell Res (1992) 0.79
Telomeres and cell division potential. Prog Mol Subcell Biol (2000) 0.78
Replicative cultures of adult human and rhesus monkey liver epithelial cells. Cancer Detect Prev (1989) 0.78